Navigation Links
Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
Date:12/8/2008

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results from two large, multi-center, randomized Phase III clinical trials of VELCADE based combinations for the induction treatment of transplant-eligible patients with previously untreated multiple myeloma (MM). Prolonged progression-free survival (PFS) was observed in one study comparing VELCADE and dexamethasone (VcD) with vincristine, adriamycin and dexamethasone (VAD), as well as in another study comparing VELCADE, thalidomide and dexamethasone (VcTD) with thalidomide and dexamethasone (TD). These data were presented at the 50th Annual Meeting of the American Society of Hematology (ASH), held December 5-9, 2008 in San Francisco, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )

"VELCADE based combinations continue to deliver high response rates, including complete responses," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "It is impressive to see that this already translates to improved progression-free survival when VELCADE regimens are used in conjunction with high dose therapy and stem cell transplantation."

VELCADE-Dexamethasone versus VAD as Induction Treatment Prior to ASCT in Newly Diagnosed Multiple Myeloma: Updated Results of the IFM2005/01 Trial (ASH/ASCO Joint Symposium)

This 482-patient Phase III trial was conducted by the Intergroupe Francophone du Myelome (IFM) cooperative group and Nantes University Hospital (France). The updated results, which were presented by Professor Harousseau, showed:

    -- The two year PFS was 69 percent in the VcD arm, compared with 60
       percent in the VAD arm (p=0.0115).
    -- Post-induction complete response (CR)/near complete response (nCR)
       rates were 15 percent in the VcD arm, compared w
'/>"/>
SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
2. Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
3. Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
4. Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control & Sexual Function in Women
5. New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
6. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
7. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
8. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
11. Portable CT Increases Chance of Stroke Survival and Recovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... NEW YORK and PLAINSBORO, ... Nordisk announced today its support of the National ... in Care , which provides support to people ... the physical and psychosocial challenges that can impede ... of six modules, Communication With Your Provider ...
(Date:9/18/2014)... and MELBOURNE, Australia , Sept. ... Biopharma today announced the appointments of Dr. Ashraf ... D.V.M ., M.S., to its Board of Directors. Dr. ... Affairs Finance at Genentech and Chief Financial Officer for ... as Vice President and Global Head of Business Development ...
(Date:9/18/2014)... NEW YORK , Sept. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... James to the position of  Senior Director of ... Clinical Research, Mr. James has established and led successful ... Europe , to facilitate the clinical development ...
Breaking Medicine Technology:Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... 2011 Egenix, Inc. -- Donald Fresne, CEO ... appointment of Nils Bergenhem, PhD as President and ... of drug development experience to the company and ... between equally-sized companies, as well as between biotech ...
... Caremark Corporation (NYSE: CVS ) will be ... at 8:30 a.m. (ET) with analysts and investors to ... (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) An audio webcast of the ... Relations portion of the CVS Caremark Web site for ...
Cached Medicine Technology:Nils Bergenhem, PhD - Newly Appointed President and Chief Scientific Officer of Egenix, Inc. 2CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call 2
(Date:9/18/2014)... (PRWEB) September 18, 2014 Research conducted ... Allegheny Health Network has documented improved survival ... surgical removal of the tumors along with stereotactic radiosurgery. ... of ASTRO (American Society for Radiation Oncology) ... uses numerous precisely focused radiation beams to treat tumors ...
(Date:9/18/2014)... Johannesburg, South Africa (PRWEB) September 18, 2014 ... organization to adopt the HABIT™ Program in ... by Indaba Health and Wellness, and distributed in South ... version of the HABIT program, which has been tailored ... , IHW HABIT™ focuses on behavior modification and chronic ...
(Date:9/18/2014)... Springs, LA (PRWEB) September 18, 2014 This past ... got a kiss from Roy at the kissing booth during the ... “Bo” Bryant Animal Shelter. “I have loved animals my whole ... with most of those animals being strays who needed a home. ... animals since I can’t take them all home!” , The CEO ...
(Date:9/18/2014)... Ottawa (September 18, 2014) A new expert ... released today by the Council of Canadian Academies, ... medicines for children. Each year about half of ... prescription drug. Much of this prescribing is done ... use), creating potential health risks., Children have historically ...
(Date:9/18/2014)... study analyses the survival rates in Spain of newborns with ... survival under 23 weeks is ,exceptional, although other factors such ... Experts from the Spanish Society of Neonatology have studied the ... under 26 weeks, taking into account that a newborn carried ... data have been drawn from the national database that gathers ...
Breaking Medicine News(10 mins):Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2Health News:Improving medicines for children in Canada 2Health News:The viability of premature babies is minimal at 22 weeks' gestation 2
... test doesn,t single out those at high risk of trouble, ... screening for coronary artery disease is of no value for ... a new study finds. , Screening is expensive, at $1,000 ... 2 diabetes who had no symptoms of heart disease did ...
... Record 1,960 Eye and Tissue Donors in 2008 ... OneLegacy, the non-profit, federally designated organ and tissue ... area, has within the last year become the ... tens of thousands in need of cornea, bone, ...
... scientists at Beth Israel Deaconess Medical Center (BIDMC) have ... part of their 2009 Creativity Awards program, which supports ... prostate cancer. , The one-year awards were made ... with BIDMC the only institution in New England to ...
... April 14 While the number of ... the registry still only includes 38 percent of licensed ... Life America this year. Yet, according to a ... their decision to donate honored, even if their family ...
... Medical Plans, Inc., a leading provider-sponsored health insurer, covering ... announced an innovative Fracture Protection Pilot Program, in cooperation ... of Actonel, a prescription drug for the treatment and ... Alliance for Better Bone Health will cover the average ...
... (Nasdaq: ROCM ) will announce quarterly results after ... Company will then hold a quarterly conference call to discuss ... p.m. central time (5:00 p.m. eastern time).This call is being ... website at www.rocm.com . To listen ...
Cached Medicine News:Health News:Heart Screening Not Effective for Type 2 Diabetics 2Health News:Los Angeles Area Non-Profit OneLegacy Grows Into World's Largest Tissue Recovery Organization 2Health News:Los Angeles Area Non-Profit OneLegacy Grows Into World's Largest Tissue Recovery Organization 3Health News:Los Angeles Area Non-Profit OneLegacy Grows Into World's Largest Tissue Recovery Organization 4Health News:BIDMC scientists receive creativity awards from Prostate Cancer Foundation 2Health News:While the Majority of Americans Express Interest in Organ and Tissue Donation, Too Few Take Steps to Register as Donors 2Health News:While the Majority of Americans Express Interest in Organ and Tissue Donation, Too Few Take Steps to Register as Donors 3Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 2Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 3Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 4Health News:Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009 2